Leon Bernal-Mizrachi
Professor and Chair
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (20)
Year:
2026
Year:
2026
Year:
2026
Pyroptosis is a form of programmed cell death characterized by the cleavage of gasdermin (GSDM) family proteins that form pores in the plasma membrane, cell rupture, and the release of pro-inflammatory cytokines. In this study, we performed immunohistochemistry for cleaved GSDMD, GSDME-N-terminal, and GSDMC in two different cohorts of diffuse large B-cell lymphoma (DLBCL), and analyzed their prognostic and immune impact. The results showed frequent cleaved GSDMD (GSDMD-N-terminal) expression. Only cytoplasmic GSDMD-N-terminal expression correlated with significantly better patient survival in two cohorts. In contrast, GSDME was mainly expressed in the vascular endothelium, correlated with significantly adverse prognostic effect. Correlating with the multiplex fluorescent immunohistochemistry (mfIHC) results, we found that cytoplasmic GSDMD-N-terminal expression was associated with increased CD38+ (activated) M1 macrophages in both cohorts, cognate interactions between live DLBCL cells and activated M1 macrophages (and T cells), and lower PD-1/PD-L1 expression in the analyzed cases. In contrast, T cell pyroptosis, lymphoma cell resistance to cell death, and phagocytosis by M2 macrophages were observed in cells with nuclear GSDMD-N-terminal expression. Bulk gene expression profiling and deconvolution analysis for patients with cytoplasmic GSDMD-N-terminal expression revealed downregulation of "Don't eat me" signaling genes, upregulation of many RNA genes, decreased frequency of "Inflammatory" lymphoma microenvironment subtype, increased abundance of prognostically favorable cell states and ecotypes, and decreased abundance of T cell exhaustion state. In summary, this study showed distinct cellular and subcellular patterns of three gasdermin proteins and their associated immune response phenotypes and prognostic effects, with implications for novel therapeutic strategies for B-cell lymphoma.
Year:
2025
Year:
2025
Background: Pyroptosis is a form of programmed cell death characterized by cleavage of gasdermin (GSDM) family proteins that form pores in the plasma membrane, cell rupture, and release of pro-inflammatory cytokines. Its pro-inflammatory potential has garnered significant research attention in recent years but has not been studied in lymphoma. Patients and Methods: We performed immunohistochemistry for cleaved GSDMD (n-terminal) in two large cohorts of diffuse large B-cell lymphoma (DLBCL) with multiplex fluorescent IHC (mfIHC) data, and analyzed for prognostic and immune impact. Results: Cleaved GSDMD was frequently expressed in DLBCL, and only the cytoplasmic (versus nuclear) form of expression correlated with significantly better patient survival in two DLBCL cohorts. To understand the expression at the single-cell level, we examined mfIHC results, which revealed that GSDMD+cells were tumor or immune cells, and varied in Ki-67, BCL2, and MYC expression. Cases with cytoplasmic cleaved GSDMD expression had higher mean and median levels of CD38+ (activated) M1 macrophages in two cohorts and lower PD-1/PD-L1 expression, as well as phenotypes of cognate interactions between live activated M1 macrophages, DLBCL cells, and T cells in spatially resolved immune landscape by mfIHC. In contrast, phagocytosis of pyroptotic lymphoma cells by M2 macrophages and cell death of T cells were observed in cases with predominantly nuclear form of cleaved GSDMD expression. Bulk gene expression profiling analysis identified a large proportion of RNA genes upregulated in DLBCLs with cytoplasmic cleaved GSDMD expression, and deconvolution analysis found decreased frequency of the “Inflammatory” lymphoma microenvironment (LME) subtype, increased frequency of cell states and ecotypes with favorable prognostic associations, and decreased frequency of T cell exhaustion states. Summary: Analysis of pyroptosis-inducing cleaved GSDMD (n-terminal) expression in a large number of DLBCL patients revealed dinstinctive cytoplasmic and nuclear expression patterns in live and pyroptotic cells associated with different prognostic and immune effects. Cytoplasmic cleaved GSDMD expression is a marker of cognate interactions between live cells (e.g., activated M1 macrophages) associated with adaptive responses and favorable prognostic effects, whereas nuclear cleaved GSDMD expression is associated with immunosuppressive mechanisms, including T cell death and phagocytosis by M2 macrophages.
Year:
2025
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL), accounting for approximately 30% of all NHL cases. DLBCL diagnosis relies on histologic examination, immunophenotyping, molecular and fluorescence in situ hybridization (FISH) analysis to differentiate it from similar NHL subtypes with overlapping morphological features, including more high-grade lymphomas like double-hit lymphoma. Because FISH is performed in a panel of single- or dual-target test format and analyzed through microscopy and manual image analysis, assessment of multiple target biomarkers can be cumbersome and expensive. As additional biomarkers for diagnosis, subtyping, prognosis, and therapeutic decision-making become available, target panels will become larger, posing additional challenges to clinical laboratories. Patients and Methods In this study, Hi-C sequencing of FFPE samples was performed to identify all genomic rearrangements by a single sequencing analysis for an unselected DLBCL case series of 159 patients, and the results were compared to FISH for the detection of clinically important variants. Results Hi-C sequencing showed superior performance compared to FISH: standard FISH for DLBCL includes testing for MYC, BCL2, and BCL6. Between FISH and Hi-C, these biomarkers were detected 105 times, of which, FISH detected 80/105 (76%) and Hi-C detected 102/105 (97%). The cohort included 4 double-hit lymphomas by FISH but Hi-C sequencing detected five. Besides DLBCL diagnostic biomarkers (MYC, BCL2, BCL6), many additional biomarkers were detected by Hi-C sequencing including variants not tested by FISH because the clinical suspicion was ambiguous and the relevant FISH probes were not used, and those not tested because the biomarkers were not thought to be common and, hence, left out of the FISH panel. In total, Hi-C sequencing detected additional biomarkers in 42 (26%) cases, including (1) variants targeted by FISH (i.e. MYC, BCL2, BCL6) but negative, (2) classification biomarkers for other lymphomas (CCND1, MALT, IRF4), and (3) those not tested because the biomarkers are not common and not included in the FISH panel. These additional biomarkers were supportive of suspected diagnosis of DLBCL versus double-hit lymphoma (24 cases), prompted reconsideration of a different diagnosis that may have led to different treatments (6 cases, e.g. mantle cell lymphoma), or biomarkers such as PDL1, ALK, and ATM which have implications for targeted therapies and/or inclusion in clinical trials (5 cases). Conclusion The Hi-C FFPE sequencing technology has the potential to improve the workflow of pathology labs for detection of a wide range of structural variants informing precision diagnosis and treatment for lymphomas.
Year:
2025
Introduction: Prolonged parenteral treatment for multiple myeloma may expose patients (pts) to cumulative side effects that can significantly impact their quality of life (QoL). Pt-reported outcomes (PROs) are important in understanding the burden of treatment and the pt experience. US MM-6 (NCT03173092), a community-based phase 4 study, demonstrated the benefit of iCT from parenteral V-based induction to all-oral ixazomib/lenalidomide/dexamethasone (IRd) in facilitating long-term proteasome inhibitor-based therapy for pts with NDMM. We present US MM-6 PRO and actigraphy data among pt subgroups that are often underrepresented in clinical trials. Methods Transplant-ineligible/delayed transplant (≥24 months) pts with NDMM without progressive disease (PD) after 3 cycles of V-based induction were enrolled to receive oral IRd (≤39 cycles or until PD/toxicity). Electronic PROs (ePROs) were assessed via questionnaires: European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30), Treatment Satisfaction Questionnaire for Medication – 9 item version (TSQM-9), and EORTC QLQ – Myeloma Module (QLQ-MY20). Actigraphy data were collected via digital devices worn by pts. Not all study sites could accommodate the wearables/ePROs. Endpoints are reported for the US MM-6 intent-to-treat (ITT) population and by subgroups: racial/ethnic minorities (non-White race or Hispanic/Latino ethnicity); renal impairment (creatinine clearance ≤60 ml/min); and low area income (<$45K/year median household income associated with the clinical site zip code). All endpoints were analyzed descriptively. Results: At data cutoff (Oct 2024 [ePROs]; May 2024 [actigraphy]), of 140 pts with IRd treatment, 135 (41 [minority], 94 [non-minority]); 136 (40 [renal impairment], 96 [non-renal impairment]); and 140 (49 [low income], 91 [non-low income]) were included in the subgroups. Among 1037 EORTC QLQ-C30, 1116 TSQM-9, and 1046 EORTC QLQ-MY20 questionnaires issued to 55, 59, and 56 pts, 988, 1063, and 998 were completed, respectively, for an average compliance rate of 95%. Mean changes from baseline EORTC QLQ-C30 global health status scores across treatment cycles were mostly less than 10 (considered the minimal important difference) indicating overall maintenance of QoL. Mean changes from baseline in TSQM-9 scores were small over the course of treatment, indicative of overall treatment satisfaction. For the EORTC QLQ-MY20 questionnaire (item 43) measuring the burden of peripheral neuropathy (PN; scale of 1–4; higher scores indicate an increase in symptoms), the mean increase from baseline score was ≤0.7 across cycles, indicating that PN symptoms did not worsen much during IRd treatment. Results of questionnaires were generally consistent across subgroups; there was more variation for some subgroups (e.g., racial/ethnic minorities and renal impairment) in which the sample sizes were very small, resulting in wider 95% confidence intervals. Overall, 103 pts had available actigraphy data (27,447 total days). Of these, 24,863 days (91%) were considered compliant (≥12 hrs of wear per day and ≥14 days of wear per cycle). Mean (standard deviation [SD]) number of daily steps in the ITT population (n=94) was 3170 (2423); across subgroups, pts had a mean (SD) of 2610 (2436)/3448 (2422) steps (minority [n=23]/non-minority [n=66]); 3447 (2218)/3079 (2488) steps (renal impaired [n=25]/non-impaired [n=68]); and 3522 (2343)/3035 (2430) steps (low [n=31]/non-low income [n=63]). Mean (SD) daily active time was 0.43 (0.34) hrs (ITT); 0.33 (0.31)/0.47 (0.34) hrs (minority/non-minority); 0.45 (0.32)/0.42 (0.34) hrs (renal impaired/non-impaired); and 0.48 (0.33)/0.40 (0.33) hrs (low/non-low income). Mean (SD) daily sleep time was 7.55 (2.71) hrs (ITT); 7.97 (3.28)/7.29 (2.45) hrs (minority/non-minority); 7.16 (2.30)/7.68 (2.82) hrs (renal impaired/non-impaired); and 6.96 (2.60)/7.76 (2.71) hrs (low/non-low income). Conclusions: ePRO and act
Year:
2025
Multiple myeloma (MM) is a malignancy marked by the clonal expansion of plasma cells. Despite therapeutic advances, MM remains incurable, especially in high-risk patients with p53 deletions or mutations, 1q gain, or IGH, MMSET, FGFR3, MAFB, or MAF translocations. To address this, we developed a novel therapeutic platform called Zip-Code Drug Conjugates (ZDCs). This approach was based on our discovery that certain transposons within circulating tumor DNA (ctDNA) enable targeting of other plasma cells (REF). Using the features of these transposable elements, we screened several synthetically engineered elements—Zip-Codes (ZCs)—for specificity and efficiency in targeting plasma cells. High-throughput screening of MM cell lines and patient samples identified two key candidates matching ctDNA specificity. We selected AluSx (ZC2) as our lead ZC due to its easy production. ZC2 showed no effect on inflammatory cytokine expression and did not activate the cGAS-STING pathway or caspases, though it did activate DNA repair enzymes. We then conjugated ZC2 with various agents to assess selective cytotoxicity. Our lead compound, KTS002, consists of DM4 (a tubulin inhibitor) linked to ZcDNA via SPDB. Native PAGE confirmed its successful conjugation. Quality testing showed that KTS002 was endotoxin-free, sterile, low in beta-glucan, and consistent in concentration, hydrodynamic size, and zeta potential. Because premature plasma release contributes to ADC toxicity, we evaluated ZDC stability. HPLC-LC Orbitrap analysis showed that KTS002 remained stable in mouse and human plasma, with half-lives of 24 hours (0.5 μg/mL) to 58 hours (1 μg/mL). In contrast, glutathione and TCEP release controls had half-lives of 48 days and 27 hours, respectively. In blood and plasma assays, KTS002 did not cause hemolysis, platelet aggregation, complement activation, or coagulation disruption. In vitro, KTS002 exhibited similar IC50 values to DM4 in various MM cell lines, with only modest cytotoxicity in non-myeloma lines (A549, DU145, MIA, BT549, HCT116). Viability and LDH release assays using LLC-PK1 and Hep G2 cells showed minimal off-target effects, suggesting low renal and hepatic toxicity. Compared to Belantamab (an anti-BCMA MM ADC), KTS002 was 1000-fold more cytotoxic in cells with p53 deletions or mutations. It also overcame resistance due to BCMA mutations (e.g., R27P), which can impair activity of anti-BCMA bispecific or CAR T cell therapies. In vivo titration showed good tolerance up to 40 mg/kg. In MM1S xenograft models, KTS002 demonstrated dose-dependent tumor suppression, with high-dose treatment outperforming bortezomib. No significant changes in blood counts or liver enzyme levels were observed. A three-day regimen of 30 mg/kg led to 90% tumor growth suppression and doubled progression-free survival. KTS002 is a promising new therapy for MM, especially in high-risk patients, offering strong efficacy with minimal toxicity. Ongoing studies are focused on dose optimization, pharmacokinetics, and safety to support IND-enabling and clinical development.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Collaborators (14)
Jose Aparicio
University of Southern California Keck School of Medicine
Karen Dybkaer
Aalborg University
Bangchen Wang
Assistant Professor
Duke University Medical Center
Youli Zu
Professor and Medical Director
Houston Methodist Hospital
Govind Bhagat
Professor and Chair
Saint Louis University School of Medicine
Ken H. Young
Professor
Duke University Medical Center
Alexander Xu
Assistant Professor
University of Maryland at College Park
Jonathan Lambird
Assistant Professor
Wake Forest School of Medicine
Fenghuang Zhan
Professor, Morrison Family Endowed Chair
University of Arkansas for Medical Sciences
Michael Boe Møller
Odense Universitetshospital
Zhenming Xu
Associate Professor
University of Texas Health Science Center at San Antonio
Alexandar Tzankov
Head Histopathology and Autopsy
University Hospital Basel
Adolfo Diaz Duque
Associate Professor
University of Texas Health Science Center at San Antonio
Markus Hansson
Professor
Sahlgrenska universitetssjukhuset
Make your next move.
Prepare your application
Review drafts before you send them.